The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

Published:2013-07-17 Issue:1 Volume:28 Page:210-212
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Touzeau C,Dousset C,Le Gouill S,Sampath D,Leverson J D,Souers A J,Maïga S,Béné M C,Moreau P,Pellat-Deceunynck C,Amiot M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2013216.pdf

Reference11 articles.

1. Labi V, Grespi F, Baumgartner F, Villunger A . Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ 2008; 6: 977–987.

2. Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maïga S et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 2011; 118: 3901–3910.

3. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 5: 375–388.

4. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 5: 488–496.

5. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 2: 202–208.

Cited by 238 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Flow cytometric expression of Bcl-2, Mcl-1, and their ratios correlates with primary and secondary cytogenetic changes and their combinations in multiple myeloma;Annals of Hematology;2024-09-12

2. Translocation (11;14) is a common cytogenetic abnormality in clonal plasma cells in monoclonal immunoglobulin deposition disease;British Journal of Haematology;2024-09-06

3. Biomarker-directed therapy in multiple myeloma;Current Opinion in Oncology;2024-08-23

4. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm;Blood Cancer Journal;2024-08-12

5. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies;Blood Advances;2024-07-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3